Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...

The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.

Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...

Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved ...

Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...

Hyderabad: Dr Reddy's Labs has informed in a BSE filing that Chirotech Technology Limited, UK a step down wholly owned ...

Healthcare: Dr Reddy's Laboratories SA has completed the acquisition through the purchase of shares of Northstar Switzerland ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) ...

Dr Reddy’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...

Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global ...

Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...